• DNDi logo
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Global Headquarters
      • DNDi DRC
      • DNDi East Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
DNDi logo
  • DNDi logo
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Global Headquarters
      • DNDi DRC
      • DNDi East Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Diseases
hepatitis-c icon

Hepatitis C

Meeting the needs of millions still waiting for affordable treatment

Home > Diseases
hepatitis-c icon

Hepatitis C

Meeting the needs of millions still waiting for affordable treatment

  • Overview
  • Facts
  • Projects & achievements

We have developed a simple-to-use, affordable cure and tested new strategies to link patients to lifesaving treatment and care. We are also working to foster the political will needed for wide-scale roll-out of test-and-treat strategies together with allies in the Hepatitis C Partnership for Control and Treatment (Hepatitis C PACT).

Hepatitis C is caused by the blood-borne hepatitis C virus that can lead to chronic liver disease, cirrhosis, cancer, and, if not treated, death. Symptoms can take decades to develop and most people living with the disease do not know they are infected. As a result, hepatitis C is a silent epidemic.

Recent years have seen a revolution in medical innovation for hepatitis C, which can now be cured with just 8 to 24 weeks of safe, simple treatment. However, just 13% of people living with the disease worldwide have benefited. In many countries, high prices remain a major barrier for ‘test-and-treat’ strategies that have the potential to eliminate hepatitis C altogether.

 
Icon people in front of globe
0 million
people have hepatitis C
Icon interrogation point
0 %
are unaware they are infected
Icon treatment bottles
0 %
have had access to treatment
Icon people
0
people die every day
SEE DISEASE FACTS

‘Hepatitis C is a “silent epidemic” because people are unaware of their infection and go untreated for years.’

Sasikala Siva, DNDi Clinical Project Manager in Kuala Lumpur, Malaysia

What we have achieved

We delivered a new treatment that is equal to the best hepatitis C drugs, at a fraction of the cost.

Loading…
Registration & access

Ravidasvir + sofosbuvir

An affordable cure to leave no one behind. We have developed a new simple-to-use, affordable treatment for hepatitis C to increase access and minimize financial burden on patients and health systems. Trial results in Malaysia showed 97% of people treated were cured.

What we are doing for people living with hepatitis C

We are now working to help foster an enabling environment for improved availability of hepatitis C diagnostics and treatments in low- and middle-income countries and supporting innovative ‘test-and-treat’ programmes in several countries.

Read more in our Annual Report
Loading…

Hepatitis C PACT

This partnership is working to foster an enabling environment for HCV testing and treatment by rolling out all-oral cures, scaling up community-based testing to help find the missing millions of undiagnosed people, and addressing domestic financial challenges that may prevent the launch and scale-up of national programmes.

Registration & access

Hepatitis C Screening in Malaysia – #MYMissingMillions

Leading by example in access and innovation. A pioneer in efforts to tackle hepatitis C, the Malaysian government is joining with DNDi partner Foundation for Innovative New Diagnostics (FIND) to pilot the use of simple rapid diagnostic tests to link more people to lifesaving treatment and care.

see all projects

Making medical history for neglected patients

We develop urgently needed treatments for neglected patients and ensure they’re affordable, available, and adapted to the communities who need them

Doctor diagnosing a man in a village with his hands on the man's neck

Sleeping sickness

Transmitted by the bite of a tsetse fly and causes severe neurological disorders

We delivered a revolutionary new drug to replace toxic treatments, and have ongoing trials to eliminate this disease

Young boy sitting on a hospital bed being examined by a nurse

Chagas disease

Causes heart and vital organ damage, after people are bitten by blood-sucking bugs

We delivered the first-ever treatment for children; now we’re searching for new drug candidates and working to boost access to care

Girl with skin lesions on her nose

Cutaneous leishmaniasis

Leaves disfiguring, life-long scars that lead to severe social stigma

We’re working to develop safer, shorter treatments for this disabling disease

Young man standing in the street

Hepatitis C

Millions are left without treatment even though effective drugs exist

We’ve delivered a treatment as simple, safe, and effective as the best drugs available today – at a fraction of the cost 

Girl looking over a fence

Visceral leishmaniasis

Is one of the world’s biggest parasitic killers, spread by the bites of sandflies

We’re working to develop a new generation of treatments to replace drugs that are painful, ineffective, and cause side effects

Healthcare workers in a hospital

COVID-19

Devasting and deadly to many, there’s too little research to help the most vulnerable

We’re accelerating research by coordinating clinical trials in low-resource settings and bringing together partners

Father walking in rural village with a cane and holding his son's hand

Filaria: river blindness

Lead to unbearable itching, disfiguring skin lesions, and even blindness

We’re working to develop a safe, effective, and affordable drug for the prevention and treatment of this debilitating disease

Patient medical examination

Cryptococcal meningitis

Without treatment, deadly for thousands of people with advanced HIV

We’re working to improve access to life-saving treatments and developing an easier-to-use formulation

Sleeping sickness

Chagas disease

Cutaneous leishmaniasis

Hepatitis C

Visceral leishmaniasis

COVID-19

Filaria: river blindness

Cryptococcal meningitis

VIEW ALL DISEASES

Stay connected

Get our latest news, personal stories, research articles, and job opportunities. 

DNDi logo
Facebook-f
Twitter
Instagram
Linkedin-in
Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License